ArticleJournal of clinical medicine2020

Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial.

Eugene Han et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.